目的 探究顺铂作用于卵巢癌后Hedgehog信号通路相关蛋白表达的变化.方法 应用免疫组织化学染色法检测80例卵巢癌标本中PTCH1蛋白表达水平与卵巢癌病理特征(病理类型、病理分级、淋巴结转移、临床分期)以及患者术前是否行新辅助化疗的关系.常规培养卵巢癌细胞OVCAR-3;顺铂干预后Western Blot法观察细胞PTCH1、CycllinD1及Gli1表达水平的变化情况;CCK-8法检测细胞增殖能力的变化.结果 PTCH1在卵巢癌组织中的表达呈阳性;PTCH1蛋白的表达在不同病理类型、临床分期、组织学分级、淋巴结转移的卵巢癌患者中,差异均无统计学意义(P﹥0.05);但经顺铂新辅助化疗的卵巢癌患者的卵巢癌组织中PTCH1的阳性率较未行新辅助化疗的患者低(P﹤0.05).实验组PTCH1、CyclinD1、Gli1蛋白的相对表达量较对照组低(P﹤0.05);在顺铂干预24 h后,相同时间点上,实验组的细胞增殖率均低于对照组(P﹤0.05).结论 顺铂可能通过干扰卵巢癌中Hedgehog通路关键因子从而影响卵巢癌的发生发展.%Objective To investigate the change of Hedgehog signaling pathway related protein levels in ovarian can-cer treated by cisplatin. Method Immunohistochemical staining was used to detect the expression of PTCH1 protein in 80 cases of ovarian cancer and to analyze the pathologic characteristics (pathologic type, pathologic grade, lymph node metastases, clinical stage), and the association with preoperative neoadjuvant chemotherapy. OVCAR-3 cells were cul-tured, and were then treated by cisplatin, Western Blot was utilized to observe the expression of PTCH1, CyclinD1 and Gli1. Result PTCH1 was positively expressed in ovarian cancer tissues;and the expression of PTCH1 in ovarian cancer were similar among patients with different pathologic type, pathologic grade, lymph node metastases and clinical stage (P>0.05);however, the positive rate of PTCH1 was lower in patients treated with cisplatin plus neoadjuvant chemothera-py compared with those who had not (P<0.05);the expression of PTCH1, CyclinD1 and Gli1 protein in the study group were lower than those in the control group (P<0.05);After 24 h treatment of cisplatin, the proliferation of ovarian cancer cells was significantly inhibited after cisplatin treatment (P<0.05). Conclusion Cisplatin may mediate the development of ovarian cancer by interfering with the key factors of Hedgehog pathway in ovarian cancer.
展开▼
